← all works
FRI0452 TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
The three-model screen
all 1,000 screened works →All three models called this out of scope.
stratum: aff_core · design weight: 5595.24 (the sample is stratified; any rate computed without the weight is wrong)
Claude Opus 4.8OUT
genre: empirical
about Canada: no
confidence: high
Conference abstract reporting dermatologic endpoints of tofacitinib from two phase 3 trials; a clinical efficacy analysis.
GPT-5.6 (high)OUT
genre: empirical
about Canada: no
confidence: low
The title identifies a clinical treatment analysis, but the abstract is missing and provides insufficient detail.
Grok 4.5OUT
genre: empirical
about Canada: no
confidence: high
Clinical phase-3 dermatologic endpoints for tofacitinib in psoriatic arthritis.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- Annals of the Rheumatic Diseases
- Topic
- Psoriasis: Treatment and Pathogenesis
- Field
- Immunology and Microbiology
- Canadian institutions
- Probity Medical Research
- Funders
- —
- Keywords
- TofacitinibMedicinePsoriatic arthritisDermatologyArthritisRheumatoid arthritisPsoriasisInternal medicine
- Has abstract in OpenAlex
- no